| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-Cannabinoid Receptor 1 (extracellular) Antibody is an antibody targeting CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IC, IF, IFC, IHC, LCI, WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor (also reported as CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor).
- Immunogen/epitope region: Extracellular, N-terminus.
- Homology note: Human - identical; mouse - 15/16 amino acid residues identical (informative for cross-species interpretation).
- Species reactivity (as provided): Human, Rat, Mouse.
- Cited use: IHC (literature use does not guarantee performance in every setup).
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
Cannabinoids have been used in Eastern medicine for many years as pain relievers.1 Δ9-tetrahydrocannabinol (THC), the major psychoactive compound in marijuana and hashish, has been shown to interact with two specific cannabinoid receptors: cannabinoid receptor 1 (CB1 receptor) and cannabinoid receptor 2 (CB2 receptor).2 The cannabinoid receptors can be distinguished by their amino acid sequences, signaling mechanisms, and tissue distributions.2 Both receptors belong to the G-protein coupled receptor (GPCR) superfamily. CB1 was shown to modulate several Ca2+ and K+ ion channels.2,3CB1 is primarily expressed in the central nervous system. However, expression of CB1 is also detected in the peripheral terminals, in non-neuronal peripheral tissues such as uterus, testes, spleen, as well as in cells of the immune system.3,4CB1 is implicated in many cellular functions such as neurotransmitter release, pain relief, cancer, and obesity.5,6 Growth inhibition of tumor cells was demonstrated following mixed CB1/CB2 agonist treatment in both prostate and non-melanoma skin cancers.5,6 Through their interaction with CB1, cannabinoid compounds stimulate appetite for sweets and palatable foods in particular, making CB1 an attractive therapeutic target for the treatment of obesity and eating disorders.7
Research relevance and current trends
- Mapping receptor/channel localization across neuronal subtypes and subcellular compartments.
- Linking trafficking or surface expression changes to activity-dependent signaling and plasticity.
- Using KO/KD or blocking-peptide concepts to strengthen antibody-based target assignment.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
- Immunohistochemistry (IHC): examine spatial distribution in tissue and relate signal to cell-type composition.
- Immunofluorescence/ICC: assess subcellular localization and co-localization with markers in cells or sections.
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
- Live cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: BLP-CR001.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-CR001; Negative control: BLP-CR001.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
